Cost-effectiveness analysis of 1-year treatment with golimumab/standard care and standard care alone for ulcerative colitis in Poland

PLoS ONE

Volumn 11, Issue 8, 2016, Pages

  Stawowczyk, Ewa ^a   Kawalec, Paweł ^b   Pilc, Andrzej ^c  

^a Linde Gaz Polska Sp z oo   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; GOLIMUMAB; MERCAPTOPURINE; MESALAZINE; PREDNISOLONE; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; COLON SURGERY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG COST; FEMALE; HIDDEN MARKOV MODEL; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; POLAND; QUALITY ADJUSTED LIFE YEAR; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; COST BENEFIT ANALYSIS; ECONOMIC MODEL; ECONOMICS; MARKOV CHAIN; QUALITY OF LIFE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; COST-BENEFIT ANALYSIS; GASTROINTESTINAL AGENTS; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; POLAND; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84983085055     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0160444     Document Type: Article

References (16)

1. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641-57. PMID: 17499606
2. Feagan BG, Reinisch W, Rutgeerts P, Sandborn WJ, Yan S, Eisenberg D, et al. The Effects of Infliximab Therapy on Health-Related Quality of Life in Ulcerative Colitis Patients. Am J Gastroenterol 2007; 102:794-802. PMID: 17324131
3. Kornbluth A, Sachar DB. The Practice Parameters Committee of the American College of Gastroenterology. Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105:501-523. doi: 10.1038/ajg.2009.727 PMID: 20068560
4. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012; 380: 1606-19. doi: 10.1016/S0140-6736(12)60150-0 PMID: 22914296
5. Farrell TJ, Peppercorn MA. Ulcerative colitis. Lancet 2002; 359: 331-40. PMID: 11830216
6. European Medicines Agency website. Summary of Product Characteristic Simponi. Available: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000992/WC500052368.pdf
7. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis. Gastroenterology 2014; 146:85-95. doi: 10.1053/j.gastro.2013.05.048 PMID: 23735746
8. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis. Gastroenterology 2014; 146:96-109. doi: 10.1053/j.gastro.2013.06.010 PMID: 23770005
9. Feagan BG, Sandborn WJ, Lazar A, Thakkar RB, Huang B, Reilly N, et al. Adalimumab Therapy Is Associated With Reduced Risk of Hospitalization in Patients With Ulcerative Colitis. Gastroenterology 2014; 146:110-118. doi: 10.1053/j.gastro.2013.09.032 PMID: 24067881
10. Arai K, Koganei K, Kimura H, Akatani M, Kitoh F, Sugita A, et al. Incidence and outcome of complications following restorative proctocolectomy. The American Journal of Surgery 2005; 190:39-42. PMID: 15972169
11. Fazio VW, Ziv Y, Church JM, Oakley JR, Lavery IC, Milsom JW, et al. Ileal Pouch-Anal Anastomoses Complications and Function in 1005 Patients. Ann. Surg., 1995; Vol. 222, No. 2, 120-127. PMID: 7639579
12. Woehl A, Hawthorne B, Morgan CL, Punekar Y, McEwan P. The epidemiology and healthcare resource use in patients with Crohn's disease: a population based UK study. Value Health 2007; 10: A355
13. Arseneau KO, Sultan S, Provenzale DT, Onken J, Bickston SJ, Foley E, et al. Do Patient Preferences Influence Decisions on Treatment for Patients With Steroid-Refractory Ulcerative Colitis? Clinical Gastroenterology and Hepatology 2006; 4:1135-1142. PMID: 16829206
14. Golimumab, ulcerative colitis. CDEC Final Recommendation. Canadian Agency for Drugs and Technologies in Health. March 19, 2014.
15. Thorlund K, Druyts E, Eapen S, Mills E. Cost-effectiveness of golimumab versus infliximab and adalimumab for the treatment of moderate to severe ulcerative colitis. Value in Health 2014; 17:A1-A295.
16. Xie F, Blackhouse G, Assasi N, Gaebel K, Robertson D, Goeree R, et al. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost Effectiveness and Resource Allocation 2009, 7:20. doi: 10.1186/1478-7547-7-20 PMID: 20003364